
































































Prospective Validation of CD-62L (L-Selectin) as Marker
of Durable Response to Infliximab Treatment in Patients
With Inflammatory Bowel Disease: A 5-Year
Clinical Follow-up
Francisco Bravo, MD1,2, Jamie A. Macpherson1, Emma Slack, PhD1, Nicolas Patuto, MD2, Julia Cahenzli, PhD1, Kathy D. McCoy, PhD1,
Andrew J. Macpherson, MD, PhD1,2 and Pascal Juillerat, MD, MSc1,2 for the SATICC (Sensitivity to Anti-TNF Inhibition in Crohn’s disease
and ulcerative Colitis) study group
INTRODUCTION: The development of biomarkers to guide management of anti–tumor necrosis factor (TNF) agents in
patients with inflammatory bowel disease (IBD) is an unmet need. We developed an in vitro blood assay
to predict patient long-term outcome with the anti-TNFa agent infliximab (IFX).
METHODS: Patients with IBDwere classified according to the shedding of anL-selectin (CD62L) from the surface of
their granulocytes in whole blood. CD62L shedding was quantified by flow cytometry before and after
drug administration. A clinical data collection from June 2012 to August 2017 with blinded IFX
management was aimed at validating the long-term predictive value of this test.
RESULTS: Among 33 patients with IBD (17 Crohn’s disease and 5 ulcerative colitis), 22 were predicted functional
responders (PFR) and 11were predicted as nonresponders (NR) according to the in vitro test. Five years
after study initiation, 72% of PFR were still treated with IFX (vs 27% in the NR group; P < 0.05), with a
median time spent under IFX of 45 vs 12months (P5 0.019), respectively. Thirty-five medicosurgical
events occurredwith amedian time to first event of 3 vs 30months (P50.023), respectively. Our assay
was the best independent predictor of staying long term on IFX (P5 0.056).
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DISCUSSION: An assay-based in vitro test for functional blockade of TNFa (CD62L shedding) provides an excellent
long-term (at 3–5 years) independent predictor of durable use of IFX in patients with IBD. Testing
patients could personalize decision making to significantly reduce costs and risk of adverse events and
complications.
SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/CTG/A491 and http://links.lww.com/CTG/A492.
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INTRODUCTION
Inflammatory bowel diseases (IBDs) (mostly Crohn’s disease
[CD] und ulcerative colitis [UC]) are immunologically mediated
chronic inflammatory diseases of the bowel causing significant
morbidity for afflicted individuals worldwide (1–5).
The treatment of IBDwith biologic agents such as anti–tumor
necrosis factor alpha (anti-TNFa) agents has been a dramatic
improvement in the management of these patients since the be-
ginning of the 21st century (6–9). In the long term, however,
many patients with IBD will progressively lose response (10,11)
despite interventions for optimization, such as dose increase and
shortened intervals of drug administration (12–14). This loss of
responsiveness (LOR) is currently understood in the context of
progressively higher serum concentrations of the anti-TNF agent
being required to treat high systemic inflammation (15). For
example, in severe UC, more anti-TNF immunoglobulins are
required (16–18) and significant loss of the therapeutic agent in
stool has been reported (19). Increased hypercatabolism or
clearance, contributing to LOR, is also favored by to the de-
velopment of AntiDrug Antibodies (ADA) (13,20,21). This sec-
ondary immune response against anti-TNF agents has been
widely reported, and the serum levels ofADAhave been proposed
as a predictor of patient response (22,23). Longitudinal studies
have also reported that low drug serum trough levels (TL) and the
development of ADA predict clinical LOR in patients receiving
anti-TNF inhibitors (15,24–28), leading to the concept of thera-
peutic drug monitoring (29,30). However, the LOR in some pa-
tients could possibly be due to a less anti-TNF driven pathway of
inflammation (31), as suggested by the good response rates in the
recent ustekinumab trial, amonoclonal antibody directly targeted
against interleukin (IL)-12 and IL-23, in TNF-refractory CD
patients (32,33). Therefore, a clinical test to measure directly the
efficacy of the blockade of the inflammatory effects of TNF on
patient primary immune cells is of interest to (i) identify patients
likely to develop LOR to anti-TNF agents from the onset of
treatment and (ii) tailor the course of treatment based on a bi-
ological understanding of each patient’s response.
CD62L (L-selectin) is an adhesion molecule on the surface of
granulocytes, monocytes, and naive T cells, which is enzymati-
cally cleaved (shedding) on activation of the cells and plays a role
in lymphocyte-endothelial cell interactions (34–36). The ex-
pression of this molecule on the cellular surface can be quantified
by fluorescently labeled specific antibodies to CD62L through
flow cytometry (37). For clinical perspective, the “shedding”
(release) of this surface molecule is used as surrogate markers for
leucocytes activation during chronic or acute inflammation and is
stimulated by TNFa. Unlike available commercial tests, which
measure static values such as serum infliximab (IFX) TL, this
assay is new in its approach because it measures the in vitro blood
cells’ efficient response to IFX administered to the patient. That is
equivalent to a functional testing, which investigates changes in
innate immunity influenced by the anti-TNF agent, IFX, by
modulating L-selectin expression (38). After having published
which factors were associated with durable response to IFX in
CD (8), our aim was to work in a translational way to validate
an in vitro test. We hypothesized that our functional test on




All patients included in this study (.17 years of age) were in
clinical remission (Harvey Bradshaw index [HBI] score or
simple clinical colitis activity index [SCCAI] score#4) on IFX
maintenance therapy in an 8-week interval and had an estab-
lished diagnosis of CD or UC. Patients were previously iden-
tified during visits to the outpatient clinic and after informed
consent were included in the SATICC (sensitivity to anti-TNF
inhibition in CD and UC) study registry from Bern University,
Switzerland. Nonresidents or patients unable or unwilling to
provide blood samples or consent were excluded. Exclusion
happened also when one of the 2 blood samples (before and
after infusion) was missing or not analyzable due to technical
problems.
Clinical data collection
At inclusion, the patient was given an enrollment questionnaire to
collect disease activity, extension, extraintestinal manifestations,
complications, previous and current treatment (including surgery),
as well as laboratory data (C-reactive protein, hemoglobin, and
calprotectin). FromJune2012 toAugust 2017, 33patientswith IBD
treated with IFX at Bern University Hospital with adequate blood
analysis for the response profile were prospectively followed with
the same clinical data collected in collection report forms by the
treating physicians (A.J.M. and P.J.) during their outpatient clinic
appointments at 3 months after enrollment and then every 3–6
months. Clinicians were blinded to the results of the CD62L
shedding and therefore took clinical symptoms-based medical
decisions (TL and ADA were unavailable). Clinical response was
defined using either a significant ($3 points) reduction of the
clinical score (HBI (39) for CD and SCCAI (40) for UC) calculated
systematically at different follow-up visits. LOR was defined as a
significant increase of the same clinical scores ($3 points) calcu-
lated at different follow-up visits. Finally, the clinical remissionwas
defined as a score of 4 or less in the HBI or SCCAI. Because of the
observational prospective design of this study and costs, no
endoscopical assessment was required and calprotectin measure-
ment was not systematically performed in 2012.
Blood collection
Blood sampleswere collected before and after (within 30minutes)
the anti-TNF antibody infusion at the hospital day clinic at the



















time of the inclusion of the patient in the study. Two blood
samples were taken before the infusion (5-mL citrated blood and
serum tube) and 1 blood sample after the infusion (5-mL citrated
blood). The citrated blood was used immediately for laboratory
analysis (TNFa resistance assay based on CD62L shedding), and
patient serum was stored at 280°C for later measurements of
drug TL and ADA at the inclusion in the study.
In-House TNFa resistance assay
Citrate blood was preincubated with 10, 0.1, or 0.001 mg/mL of
IFX for 15 minutes at room temperature. The IFX-treated blood
was then stimulated with human recombinant TNF (R&D,
Minneapolis, MN) with a top concentration of 2 mg/mL or with
lipopolysaccharide (LPS) (R&D) with a top concentration of 10
mg/mL and incubated at 37°C, 5% CO2 for 45 minutes. After
incubation, the stimulated cells were washed with 1% bovine
serum albumin/phosphate-buffered saline and stained with 1%
bovine serum albumin/phosphate-buffered saline containing 1-
mg/mL FITC-anti-human CD62L (Biolegend, San Diego, CA)
and 2-mg/mL APC-anti-human CD33 (Biolegend). Cells were
then lysed with 10% Fluorescence-activated cell sorting (FACS)
lysing solution (BD Biosciences, San Diego, CA) and acquired on
a FACSarray bioanalyzer (BDBiosciences). FlowJo FACS analysis
software (Tree Star, Ashland, OR) was used to distinguish be-
tweenmonocytes and granulocytes by CD33 expression and side-
scatter. The mean fluorescence intensity of the FITC signal was
recorded and plotted against the concentration of TNF or LPS
used to stimulate the blood sample using Prism GraphPad
graphing software (GraphPad Software, La Jolla, CA) (Figure 1).
Nonlinear regression curves were fitted and the logEC50 values
were calculated, corresponding to the concentration of either
TNF or LPS required to induce half the maximal granulocyte or
monocyte CD62L shedding (Figure 1). This allowed investigating
whether therapeutic TNFa inhibitors prevented the loss of
CD62L expression in the blood of patients with CD or UC. A
difference of more than 0.5 in the log of the EC50 before and after
infusion was considered as a marker of predicted durable re-
sponse (efficacious TNFa blockade). This test was validated in
another study already published by Erdoes et al. (37,41).
Detection of preinfusion levels of IFX and antibodies directed
against the medication
In addition to measuring preinfusion levels of IFX, the mea-
surement of the presence of endogenous antibodies against the
prescribed TNF inhibitor was assessed with a drug sensitive
assay (Lisa-Tracker Premium IFX kit [Theradiag, Marne la
Vallée, France]). All standards and controls were measured in
duplicates in a blinded fashion in an external laboratory
(Unilabs Laboratories, Cor Lab Ouest Coppet, Switzerland)
which has established a validated and standardized procedure
used in daily clinical activity in Switzerland. The lower limit of
quantification for serum levels of IFX was 0.1 mg/mL. The
lower and upper limits of quantification for anti-IFX ATI were
10 and 200 ng/mL.
Data handling and statistical analyses
Data from the enrollment and clinical follow-up recorded on
paper collection report form (questionnaire) and then digitalized
using Microsoft Office Professional Plus Excel 2016 (Microsoft
Corporation, Redmond, WA). All data were then pooled and
processed with Stata MP, v.16.1 (StataCorp LP, College Station,
TX) and RStudio (Boston, MA). The Student t test, Wilcoxon
rank-sum test, and Pearson x2 test were all used in testing data
normality between groups. Logistical regression analyses were
performed to identify predictive factors of having a good func-
tional blockade of TNFa with IFX (responders) after adjustment
for demographics, duration of disease, and baseline comorbid-
ities. To identify factors associated with the need to change IBD
treatment strategy, univariate logistic modeling and multivariate
logistic modeling were performed. Univariate variables with a P
value less than 0.20 were used in the multivariate logistic model.
Survival analyses for time to first event were calculated according
to the Kaplan-Meier method. In our survival analyses, events are
defined as an intervention leading to a therapeutic strategy
change (IFX interval shortening or dose adjustment, addition of
IBD-specific medications, switch within or out of class). Such
events were LOR to IFX, clinically defined IBD flare-up, allergic
reaction, IBD medication-related adverse event (AE), and auto-
antibodies against IFX. A P value of less than 0.05 was considered
to be statistically significant.
Figure 1.CD62L granulocyte shedding in 2 different patients asmeasured
by mean fluorescence intensity after incubation of citrate blood with
different infliximab (IFX) concentrations. (a) Predicted functional re-
sponder (PFR). (b) nonresponder (NR). TNF, tumor necrosis factor.
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Table 1. Demographics of included patients with IBD according to the predicted response by CD-62L shedding assay
Baseline characteristics
Predicted response by CD-62L shedding assay
PResponders (PFR) Nonresponders (NR)
All patients n5 22 n 5 11
Female sex, n (%) 9 (40.9) 6 (54.5) 0.711
Age, median (IQR) 39.00 (29.50–46.25) 29.00 (27.50–39.00) 0.276
Age at diagnosis, median (IQR) 22.5 (18.00–29.75) 23 (18.00–29.00) 0.985
Age category (%)
A1 3 (13.6) 2 (18.2) 0.770
A2 15 (68.2) 8 (72.7)
A3 4 (18.2) 1 (9.1)
Diagnosis of CD (vs UC), n (%) 17 (77.3) 8 (72.7) 1.000
Active smoking at inclusion, n (%) 15 (68.2) 7 (63.6) 1.000
Total follow-up duration,mo,median (IQR) 48.00 (44.50–51.50) 53.00 (37.50–59.50) 0.688
Previous IBD-related surgery, n (%) 5 (22.7) 0 (0.0) 0.230
Months of IFX before inclusion, median
(IQR)
38.50 (4.50–50.75) 18.00 (9.00–35.00) 0.566
Comedications at inclusion, n (%)
5ASA compounds 3 (14) 2 (18) 1.000
Antibiotics 0 (0.0) 0 (0.0)
Steroids 1 (4.5) 4 (36.4) 0.059
Thiopurines 7 (31.8) 1 (9.1) 0.315
CRP at enrollment, median (IQR) 2.00 (2.00–3.50) 4.00 (2.00–10.00) 0.059
CD patients n5 17 n 5 8
Female sex, n (%) 5 (29.4) 4 (50.0) 0.580
Disease location (Montreal classification),
n (%)
L1 ileal 5 (29.4) 1 (12.5) 0.554
L2 colonic 3 (17.6) 1 (12.5)
L3 ileocolonic 9 (52.9) 6 (75.0)
1L4 upper disease, n (%) 11 (64.7) 5 (62.5) 1.000
Perianal disease, n (%) 7 (41.2) 1 (12.5) 0.330
Disease behavior (Montreal classification),
n (%)
B1 8 (47.1) 5 (62.5) 0.734
B2 5 (29.4) 2 (25.0)
B3 4 (23.5) 1 (12.5)
Previous IBD-related surgery, n (%) 5 (29.4) 0 (0.0) 0.238
HBI at inclusion, median (IQR) 1.00 (0.00–2.00) 0.00 (0.00–3.50) 0.804
CDAI at inclusion, median (IQR) 41.00 (18.00–71.75) 51.00 (22.50–127.25) 0.581
UC patients n 5 5 n 5 3
Female sex, n (%) 4 (80.0) 2 (66.7) 1.000
Disease behavior, n (%)
E1 proctitis 0 (0.0) 0 (0.0) 0.346
E2 left-sided colitis 3 (60.0) 0 (0.0)
E3 pancolitis 2 (40.0) 3 (100.0)
Previous IBD-related surgery, n (%) 0 (0.0) 0 (0.0)




















Licensed physicians at the Inselspital (A.J.M. and P.J.), University
Hospital Bern, Switzerland, collected blood samples and clinical
data frompatients suffering fromCDandUCandhealthy donors.
The study was approved by the Bern Cantonal Ethics Commis-
sion (Ref. No. KEK-BE: 132/12), and signed informed consent
was obtained from each of the participants.
RESULTS
Patient population and clinical characteristics
We recruited 46 patients with IBD in IFXmaintenance therapy at
our day clinic. They gave consent to participate in the study and
provided 104 blood samples (mean 2.26 per patients). However, 8
could not be included due to technical errors, and 5 patients did
not reach the required 2 blood samples timepoints collections
(before and after infusion) which lead to 33 IBD (25 CD and 8
UC) patients included for the final analysis. The assay showed a
functional blockade of IFX (predicted functional response: PFR)
for 22 patients (17 CD and 5 UC), whereas 11 (8 CD and 3 UC)
had no functional response (nonresponders: NR) to IFX
(Figure 1).When comparing both groups, there was slightlymore
steroid use at inclusion in the NR vs PFR group (P 5 0.059).
However, the duration of previous IFX therapy at admission was
not statistically different between in vitro PFR vs NR patients
(mean 32 6 27 vs 25 6 21 months, P 5 0.57), and none of the
other clinical characteristics reached statistical significance
(Table 1).
Clinical and biological prospective follow-up
During the 5 years of the study, 7 patients (21%) (3 in the NR and
4 in the PFR groups, respectively) were lost to follow-up. Total
mean follow-up time was 46 months (SD613.8, range 7–62; 127
patient-years follow-up) and was similar in both PFR and NR
groups (resp. 45 and 47 months, P 5 0.7). Thirty-five medi-
cosurgical events occurred (7 medication-related AEs, 1 treated
cytomegalovirus colitis, 21 flares treated with medication, 3 in-
testinal resections, and 3 operations of fistula) (see Supplemen-
tary Figure 1, Supplementary Digital Content 1, http://links.lww.
com/CTG/A491), and two-thirds of them during the first 3 years.
Between year 1 and year 3 of follow-up, the proportion of
patients who stayed stable without need for intervention (e.g.,
interval shortening, steroids, or switch of medication) were 16/21
(76%; 1 AE) in PFR vs 1/9 (11%, 2 AEs) in NR (P, 0.001). In the
PFR group, 4 of the 5 interventions were successful, whereas only
half of the 8 interventions of the NR led to clinical improvement
or remission.
The proportions of patients still under IFX and anti-TNF
agents were, respectively, 72% vs 36% (P5 0.1) at 3 years and 72%
vs 27% at 5 years (P , 0.05). The median time spent under IFX
therapy after induction was 12 (interquartile range [IQR] 3.5–35)
months in the NR groups vs 45 (IQR 34.25–48.5) months in the
PFR group (P 5 0.02) (Figure 2).
The mean delta of calprotectin between first year and second
year of follow-up was 1.3 (SD685) for PFR and 261 (SD6255)
for NR (P, 0.001). The mean calprotectin during the whole first
3 years of follow-up (1 measurement per patient per year avail-
able) was 119 (6139 SD) for PFR and 310 (6226 SD) forNR (P,
0.001).
A whole study intervention-free survival analysis
Interventions were defined as any significant clinical situation
that led to a change of in the IBD-specific treatment strategy (dose
escalation, interval shortening, in-class switch, out-of-class
switch, and IFX cessation) during the whole observation period.
Median time to first intervention was 3 months (IQR 1.5–12) in
theNR group vs 30months (IQR 9.75–42.75) in the PFR group (P
5 0.04). Among patients whose disease was inactive at admission,
median time to first event was 31 (IQR 19.5–46.3) months in the
PFR group and 12 (IQR 12–48) months in the NR group (P 5
0.6). Intervention-free survival was significantly worse (P 5
0.027) for patients who were predicted NR by our assay when
compared with patients who were predicted responders (Kaplan-
Meier; Figure 3). In particular, body mass index, smoking, and
Table 1. (continued)
Baseline characteristics
Predicted response by CD-62L shedding assay
PResponders (PFR) Nonresponders (NR)
SCCAI at inclusion, median (IQR) 3.00 (2.00–4.00) 4.00 (2.00–5.50) 0.651
MTWI at inclusion, median (IQR) 4.00 (1.00–5.00) 2.00 (1.00–5.00) 0.88
5ASA, 5-aminosalicylic acid; CD, Crohn’s disease; CDAI, Crohn’s Disease Activity Index; CRP, C-reactive protein; HBI, Harvey Bradshaw Index; IBD, inflammatory bowel
disease; IFX, infliximab; IQR, interquartile range; MTWI, Modified Truelove and Witts Index; PFR, predicted functional responders; SCCAI, simple clinical colitis activity
index; TNF, tumor necrosis factor; UC, ulcerative colitis.
Figure 2. Infliximab treatment duration after inclusion. Dots represent
individual patients and the duration of infliximab (IFX) therapy in months,
from inclusion to treatment cessation or end of follow-up period. Data are
represented asmedians6 interquartile ranges (Wilcoxon test). TNF, tumor
necrosis factor.
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concomitant thiopurine therapy or steroid use did not signifi-
cantly influence the outcome.
Identification of predictors for interventions and IFX cessation
Therapeutic strategies over the 5 years of follow-up are depicted
in Figure 4. For our analyses, IBD-related surgery as a therapeutic
decision was considered as an out-of-class switch. We performed
first univariate and then multivariate conditional logistic re-
gression to identify risk factors for the need to stop IFX at the end
of each follow-up year (Table 2). There were no identified sig-
nificant predictors for the first 2 years of assessment. At 3 years of
follow-up, predicted response using our assay was independently
and almost significantly associated with the need to discontinue
IFX (P5 0.056), whereas statistical significance was not reached
for the years 4 and 5.
TL and antibody measurement
TL and ADA measurement could be performed retrospectively
(not commonly accessible in 2012) on blood serum samples taken
at inclusion in 27 patients (82%; 19 PFR and 8 NR). Four patients
developedADA (2 and 2 in the PFR andNR groups, respectively).
Antibodies were detected after 1 and 3.2 years, after performing
the anti-TNF assay for the 2 patients in the NR group and, re-
spectively, 2.5 and 2.8 years in the PFR group. There was no
significant difference inmeanTL values betweenPFR andNR (3.6
vs 3.8; P5 0.9), and only 35% of all patients had a therapeutic TL
(.3 mg/mL) despite an appropriate dosage of 5 mg/kg.
As these analyses were performed retrospectively, the clini-
cians were blinded to TL and ADA values, which led to following
interpretation of blinded interventions: In the NR group, an in-
fusion interval reduction was successful in 2 patients who, how-
ever, had already optimal TL, whereas this intervention failed in 2
other patients (only 1 with low TL). In the PFR group, all inter-
ventions that could have been attempted—based on TL and
ADA—have eventually not been performed (clinicians blinded),
but were clinically (favorable outcome) not required.
DISCUSSION
In the present study, we assess a novel in vitro laboratory assay for
its relevance in predicting durable clinical response of CDandUC
patients to IFX, a therapeutic anti-TNFa antibody. Thirty-three
patients with IBD in remission on maintenance treatment with
IFXwere tested and classified according to the results of the assay.
A significantly higher number of events needing an intervention
(e.g., interval shortening, steroids, or switch of medication) was
observed in the predicted NR (45% vs 12% of events per patient
year) compared with the PFRs during a 5-year follow-up. This
essay also could predict (P 5 0.056) a durable response to IFX
therapy at a 3-year foresight, with a much longer benefit of the
TNFa blockade (45 vs 12 months, P 5 0.02) in the PFR group.
To the best of our knowledge, no other previous study has
analyzed functional blockade of TNFa in the field of IBD by using
the CD62L shedding assay as surrogate marker. Indeed, this
CD62L shedding assay, despite not being so far identified as
specific for IBD, allows for direct quantification of the immu-
nologically relevant function of blood granulocytes and mono-
cytes. This suggests an increased value compared with methods
quantifying cytokine levels in serum or cell surface phenotypes.
Our assay developed by Emma Slack was also used by Erdoes
et al. (41) who could demonstrated that the surgical technique of
coronary bypass influences the postsurgical systemic in-
flammatory response through quantification of the CD62L
shedding. This was the first publication, which validated this
technique that uses the cleavage of the membrane-bound CD62L
molecules as a surrogate parameter for early cell activation.
Interpreting this finding in our patients may bemore complex
since it potentially reflects as much the systemic inflammation in
our patients (to note, the inflammatory markers (Table 1) where
similar in both groups) as of the neutrophil responsiveness, the
Figure 3. Kaplan-Meier curves of time to first event in months, stratified by response prediction through the anti–tumor necrosis factor assay. P value
calculated using the log-rank test. NR, nonresponders; PFR, predicted functional responders.



















latter being modulated by the drug (IFX) in response to microbial
stimulation (LPS molecule) or an inflammatory signal (TNFa)
(42). Therefore, our method provides different information a kind
of an in vitromeasurement of an in vivo function of the cells of an
individual patient using fresh blood samples. The disease activity
characterizedby theC-reactive protein value at baseline and the use
of steroids was different in the 2 groups and could therefore have
played a role, as already know from the literature, in anti-TNF
inhibitor response. However, these factors did not influence sig-
nificantly the outcome in the univariate and multivariate analysis.
Other studies pave the way to a tailored IBD therapy based on
a specific laboratory test. Wojtal et al. evaluated the efficacy of the
various anti-TNFa antibodies and identified the Fc gamma
receptor CD64 as central to the mechanism of LOR to IFX, but
not to certolizumab pegol (43). Its expression seems to be
interferon-gamma induced. Similar and somewhat more com-
plex examples of tailoring therapy to laboratory test results have
been already described in the literature (44). Somemolecules have
been identified through translational research and linked to anti-
TNF response or management, such as oncostatine M (45) and
TNFa in endoscopical biopsies (46). Serum IL-9 levels were also
recently suggested as a new interesting marker of CD activity
and linked to response to anti-TNF (47), and the IL-23 pathway
activation (with presence of apoptosis-resistant intestinal
TNFR2 1 IL23R 1 T cells) is linked to a LOR to anti-TNF
agents (31). The Israeli IBD network group developed the first
predictive assay based on the analysis-embedded tissue. They
could identify predictors of nonresponse to anti-TNFa agents,
such as a high proportion of plasma cells in the biopsies and an
upregulation of the triggering receptor expressed on myeloid
cells (48). This TREM1 differential expression has been con-
firmed by the Verstockt et al. (49), from Leuven who identified,
however, downregulation associated with mucosal healing.
The expression of other candidates genes or group of genes
reported associations of TLR2, TLR4, TLR9, TNFRSF1A, IFNG,
IL6, and IL1B with response to IFX in IBD (50,51). HLA-
DQA1*05 (52), HLA-DRB1 (53), and FCGR3A (54) alleles has
also been recently associated with immunogenicity to IFX (50).
Finally, a recent single-cell analysis of inflamed tissues from CD
patients demonstrates that when a cellular module called
GIMATS (IgG plasma cells, Inflammatory Mononuclear
phagocytes, Activated T cells, and Stromal cells) is present, there
is a strong correlation with a failure of anti-TNF agents to induce
steroid-free remission (55).
The strength of our study is that it can explore a new aspect of
the response to anti-TNF agent based on a live, cellular-based
assay also using blood as opposed to existing in vitro assays using
drug andADAdetection. The validation of the predictive value of
Table 2. Univariate and multivariate logistic regression models to evaluate risk factors for infliximab cessation in the first 3 years after
inclusion and anti-TNF assay testing
Univariate model Multivariate model
OR (95% CI) P OR (95% CI) P
Male sex 0.31 (0.06–1.37) 0.13 0.33 (0.03–2.27) 0.27
Age category (%)
,40 1.0 (reference) 1.00
$40 0.79 (0.11–6.87) 0.81
Diagnosis of UC (vs CD) 0.67 (0.08–3.85) 0.67
Active smoking at inclusion 0.69 (0.12–3.35) 0.66
Previous IBD-related surgery 0.40 (0.01–3.21) 0.44
Comedications at inclusion
Steroids (%) 10.86 (1.32–233.25) 0.05 5.00 (0.38–129.23) 0.24
Thiopurines (%) 0.51 (0.06–2.85) 0.47
Active disease at enrollment 4.72 (0.89–29.5) 0.08 3.17 (0.37–29.2) 0.28
Predicted nonresponder (NR) 9.91 (1.91–66) 0.0096 7.14 (1.01–67.65) 0.056
Bold values indicates statistical significance.
CD, Crohn’s disease; CI, confidence interval; IBD, inflammatory bowel disease; OR, odds ratio; TNF, tumor necrosis factor; UC, ulcerative colitis.
Figure 4. Therapeutic outcomes per patient at the end of each follow-up
year, stratifiedbypredicted responsegroups. IFX, infliximab;NR,predicted
nonresponders; PFR, predicted functional responders.
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this test over a long, well-phenotyped, clinical follow-up is an-
other important aspect.
The need for fresh blood and rapid analysis (stable results
when performed within 3 hours [data not shown]) presents
limitations to the daily clinical use of this test. On the other hand,
the result of the assay was found to be stable over time within
individuals. In selecting patients for inclusion in this study, we
were limited to individuals receiving maintenance therapy with
IFX at the day clinic. This could arguably present a selection bias
toward good responders to the drug. This also implies a specific
indication bias for complicated refractory cases (e.g., higher
proportion of upper gastrointestinal and fistulizing and pre-
viously operated CD). As this study has been performed at a time
when therapeutic drug monitoring was not available, we could
demonstrate that retrospectively almost two-thirds of the patients
were probably underexposed to IFX and not systematically
treated with combination therapy, which was less “en vogue” in
Europe than in the United States at that time. All this could have
impacted on antibody formation; however, the retrospective
testing did not show any difference between the 2 groups. En-
doscopy and histology as standard evaluations of treatment re-
sponse were financially not possible in the protocol of our study.
However, an endoscopical examination could be performed as
standard of care in some patients if required by the treating
physician to take his decision.
Sample size is another issue and might be a limitation to the
validity and generalizability of our results. In particular, the small
number of individuals forced us to combinedCDandUCpatients
when analyzed in logistic regression or survival analyses. The
rationale for that was that both diseases have a similar response
rate to anti-TNF agents in randomized clinical trials and com-
parable complication rates.
IFX remains the first-line anti-TNF agent in numerous countries
in the management of patients with IBD. Therefore, many patients
eventually lose response to IFX (10,56) and experience significant
adverse outcomes when flare-ups or medication-related AEs hap-
pen, generating increased costs. Literature reviews assert the current
need for a better understanding of the immune system of the host in
refractory IBD to guide therapeutic strategies toward new classes of
molecules (31,57). Our data show that an in vitro test reflecting the
neutrophil reactivity to anti-TNF agents could help personalizing
IBD therapy by identifying patients who would be long-term re-
sponders beyond the first year of anti-TNFa treatment. Indeed, all
predicted responders still were under anti-TNF treatment 3–5 years
after the assay had been performed.
Further investigation on the role of CD62L (L-selectin) is re-
quired to better understand its importance regarding other families
of molecules used in the treatment of immune-induced in-
flammation, such as anti-integrins and S1P inhibitors. In example,
beside its role in leucocytesmigration, L-selectin (CD62L) has been
suggested to play a central role in adaptive immune response by
initiating lymphocyte recirculation through the lymph nodes (38),
whereas in remitting, multiple sclerosis treated with natalizumab-
reduced L-selectin (CD62L) expression in T cells in cryopreserved
samples has been proposed as a biomarker of pre-PML (pro-
gressive multifocal leukoencephalopathy) state (58–60).
CD62L (L-selectin) shedding is the first validated test of
functional blockade of TNFa in patients with IBD for long-term
prediction of stable disease state under anti-TNF inhibition;
this live assay seems to perform better than TL and ADA mea-
surements. This cheap and simple assay could be used in clinical
practice to provide a quick answer to the treating physician. This
would help him in the decision-making process toward more
personalized medicine by rationally identifying patients who
might benefit most from anti-TNF treatment or should be early
switched to another class of drugs (anti-integrin/anti-IL12/23) to
minimize interventions (treatment optimization) and reduce
costs and risk of AEs.
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Study Highlights
WHAT IS KNOWN
3 Thirty percent of patients will be primary nonresponders to
anti-TNFa, and 30%–40% of the responders will lose
response over time.
3 The mechanisms behind TNFa inhibition and loss of
responsiveness (LOR) to anti-TNF agents in patients with
inflammatory bowel disease (IBD) are poorly understood.
3 Long-term prognostic markers of therapeutic efficacy are
required for ensuring successful clinical treatment.
WHAT IS NEW HERE
3 An assay using CD62L (L-selectin) shedding on the
leucocytes surface after LPS or TNFa stimulation showed a
high value in predicting a maintained long-term response in
anti-TNF–treated IBD patients.
3 This functional test seems to perform better than trough level
and antidrug antibodies measurements as the LOR can be
dissected functionally objectively and distinguished from
antibody levels and complex formation with the drug.
TRANSLATIONAL IMPACT
3 This assay can be use in clinical practice to optimize decision
making and reduce interventions (optimization and LOR) or
complications (fistula and stenosis) and surgeries.
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